Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06048705 · ClinicalTrials.gov registry record · Phase 1
Study of GSK3901961 In Previously Treated Advanced (Metastatic OR Unresectable) Synovial Sarcoma/ Myxoid/Round Cell Liposarcoma, and Previously Treated Metastatic Non-Small Cell Lung Cancer
A Phase 1 study, sponsored by Adaptimmune.
- Terminated
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT06048705 is a Phase 1 study that was terminated before completion, run by Adaptimmune. The registered enrollment target is 7 participants.
The verdict
NCT06048705, a Phase 1 study, was terminated before completion, sponsored by Adaptimmune.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
The primary purpose of this sub study is to assess the safety, tolerability and determine recommended Phase 2 dose (RP2D) of GSK3901961 in HLA A\*02:01, HLA-A\*02:05 and/or HLA A\*02:06 positive participants with New York esophageal squamous cell carcinoma (NY ESO 1) and/or Cancer testis antigen 2 (LAGE 1a) positive previously treated metastatic Non-Small Cell Lung Cancer (NSCLC) and previously treated, advanced (metastatic or unresectable) Synovial Sarcoma/ Myxoid/Round Cell Liposarcoma SS/MRCLS.
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG GSK3901961
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2021-03-09 |
| Est. Completion | 2023-06-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06048705
The ClinicalTrials.gov registry entry for NCT06048705 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Adaptimmune, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT06048705 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06048705 about?
NCT06048705 is a clinical study titled "Study of GSK3901961 In Previously Treated Advanced (Metastatic OR Unresectable) Synovial Sarcoma/ Myxoid/Round Cell Liposarcoma, and Previously Treated Metastatic Non-Small Cell Lung Cancer". The primary purpose of this sub study is to assess the safety, tolerability and determine recommended Phase 2 dose (RP2D) of GSK3901961 in HLA A\*02:01, HLA-A\*02:05 and/or HLA A\*02:06 positive participants with New York esophageal squamous cell carcinoma (NY ESO 1) and/or Cancer testis antigen 2 (...
What is the current status of trial NCT06048705?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2021-03-09. Estimated completion is 2023-06-08.
What interventions are being tested in trial NCT06048705?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), GSK3901961 (DRUG).
Who is sponsoring clinical trial NCT06048705?
This trial is sponsored by Adaptimmune, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.